Cybin Inc. (CYBN) — Cybin announced it would voluntarily transfer its U.S. listing from NYSE American to the Nasdaq Global Market and do business as Helus Pharma, trading under the new ticker HELP instead of CYBN.
The company said its shares would stop trading on NYSE American at the close on January 2, 2026 and begin on Nasdaq on January 5, framing the move as aligning the late-stage developer with a larger biopharma peer group to boost investor visibility.
Source: tipranks.com
For the rest of that week's sector news, read our week in review.